ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical research"

  • Abstract Number: 2286 • 2013 ACR/ARHP Annual Meeting

    Reliability and Smallest Detectable Difference Of The Patient Global Assessment, Pain and Fatigue In Rheumatoid Arthritis Patients

    Paul Studenic1, Josef S. Smolen2,3 and Daniel Aletaha4, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, 2PsAID taskforce, EULAR, Zurich, Switzerland, 32nd Department of Medicine, Krankenhaus Lainz, Vienna, Austria, 4Department of Internal Medicine III, Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: Patient reported outcomes (PRO) represent an important part of outcomes assessment in rheumatoid arthritis (RA) patients. The Patient Global Assessment (PGA) is an essential…
  • Abstract Number: 2050 • 2013 ACR/ARHP Annual Meeting

    Arthralgia Occurring Under Aromatase Inhibitor Treatment For Breast Cancer.  A Prospective Study

    Daniel Wendling1, Helene Letho-Gyselinck1, Xavier Guillot2, Clément Prati3 and Xavier Pivot4, 1Service de Rhumatologie, Minjoz University Hospital, Besancon, France, 2Department of Rheumatology, CHRU Besançon, Besançon, France, 3Service de Rhumatologie, CHU J Minjoz, Besancon, France, 4Oncology, CHRU Besançon, Besançon, France

    Background/Purpose: Treatment with third generation aromatase inhibitors (AI) is associated with occurrence of arthralgia, with an incidence ranging from 25 to 45 %. In these…
  • Abstract Number: 1925 • 2013 ACR/ARHP Annual Meeting

    Patient Satisfaction with an Associate Teaching Hospital Clinical Trial Unit In North-East London

    Genevieve Casey1, Carey Tierney2, Hasan Tahir3, Simon Donnelly3 and Judith Bubbear3, 1Barts and the London Medical School, London, United Kingdom, 2Whipps Cross Clinical Research Unit, Barts Health NHS Trust, London, United Kingdom, 3Rheumatology, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Compared to patient satisfaction with general medical care little is known about patient satisfaction within clinical trials. Clinical trials are a time and resource…
  • Abstract Number: 1526 • 2013 ACR/ARHP Annual Meeting

    Stable Clinical and MRI Response In Patients With Early Axial Spondyloarthritis After 3 Years Of Continuous Treatment With Etanercept, Data Of The Esther Trial

    In-Ho Song1, Kay-Geert A. Hermann2, Hildrun Haibel1, Christian Althoff3, Denis Poddubnyy4, Joachim Listing5, Anja Weiss6, Ekkehard Lange7, Bruce Freundlich8, Martin Rudwaleit9 and Joachim Sieper4, 1Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, 2Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 3Radiology, Charite Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, 4Charité Universitätsmedizin Berlin, Berlin, Germany, 5German Rheumatism Research Center, Berlin, Germany, 6German Rheumatism Research Centre, Berlin, Germany, 7BU Specialty Care, Pfizer Pharma AG, Berlin, Germany, 8University of Pennsylvania, Philadelphia, PA, 9Endokrinologikum, Berlin, Germany

    Background/Purpose:     < style="text-align: justify;">In patients with early axial spondyloarthritis (SpA) with a disease duration of 10 years) where BASDAI50 response rates of 47%…
  • Abstract Number: 1386 • 2013 ACR/ARHP Annual Meeting

    Intracellular Concentration Of Methotrexate Is Influenced By Polymorphisms Of Gamma-Glutamyl Hydrolase Gene In Japanese Patients With Rheumatoid Arthritis

    Tatsuhiro Yamamoto, Mai Kawazoe, Emiko Shindo, Natsuki Fujio, Kotaro Shikano, Kanako Kitahara, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Kaichi Kaneko, Natsuko Kusunoki, Yoshie Kusunoki, Kenji Takagi, Tomoko Hasunuma, Hirahito Endo and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    Background/Purpose: Methotrexate (MTX) is an anchor drug for treatment of rheumatoid arthritis (RA). Appropriate effective and/or tolerable doses of weekly pulse MTX therapy vary widely…
  • Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier

    Masahiro Tada1, Tatsuya Koike2, Akihiro Tamori3, Tadashi Okano1, Yuko Sugioka1, Kenji Mamoto1, Kentaro Inui4 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, 4Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology